Inspire Medical Systems (NYSE:INSP) Issues FY 2025 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.900-1.000 for the period, compared to the consensus EPS estimate of 1.010. The company issued revenue guidance of $900.0 million-$910.0 million, compared to the consensus revenue estimate of $903.9 million.

Inspire Medical Systems Trading Up 5.3%

NYSE:INSP opened at $90.64 on Wednesday. The company has a market capitalization of $2.63 billion, a P/E ratio of 61.66, a price-to-earnings-growth ratio of 9.33 and a beta of 1.14. The firm has a 50-day moving average price of $79.42 and a two-hundred day moving average price of $110.08. Inspire Medical Systems has a twelve month low of $70.77 and a twelve month high of $216.01.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The company had revenue of $224.50 million for the quarter, compared to the consensus estimate of $220.39 million. During the same quarter in the prior year, the firm earned $0.60 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. On average, equities research analysts predict that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its board has initiated a share repurchase plan on Monday, August 11th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 8.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, November 4th. Lake Street Capital set a $150.00 price objective on Inspire Medical Systems and gave the company a “buy” rating in a research note on Tuesday, August 5th. Piper Sandler restated an “overweight” rating and issued a $135.00 target price (down from $150.00) on shares of Inspire Medical Systems in a report on Tuesday, November 4th. Wall Street Zen downgraded Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, July 26th. Finally, Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, October 27th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $133.88.

Insider Buying and Selling at Inspire Medical Systems

In other news, CFO Richard Buchholz sold 11,000 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the completion of the sale, the chief financial officer directly owned 44,867 shares of the company’s stock, valued at $4,190,129.13. The trade was a 19.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSP. US Bancorp DE grew its position in Inspire Medical Systems by 36.0% during the third quarter. US Bancorp DE now owns 2,779 shares of the company’s stock valued at $206,000 after acquiring an additional 736 shares during the period. Public Sector Pension Investment Board raised its holdings in shares of Inspire Medical Systems by 6.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 100,505 shares of the company’s stock worth $13,043,000 after purchasing an additional 6,445 shares during the period. FORA Capital LLC acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at about $220,000. State of Tennessee Department of Treasury grew its holdings in shares of Inspire Medical Systems by 11.3% during the 2nd quarter. State of Tennessee Department of Treasury now owns 16,445 shares of the company’s stock worth $2,134,000 after purchasing an additional 1,666 shares during the period. Finally, Soleus Capital Management L.P. grew its holdings in shares of Inspire Medical Systems by 179.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 109,000 shares of the company’s stock worth $14,145,000 after purchasing an additional 70,000 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.